Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624390 · ClinicalTrials.gov registry record · NA
Sepraspray™ Laparoscopic Myomectomy Study
A NA study of Laparoscopic Myomectomy, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
- 3
- Study locations
NCT00624390 is a NA study of Laparoscopic Myomectomy that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 41 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT00624390, a NA study of Laparoscopic Myomectomy, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is to obtain preliminary data of the safety and effectiveness of Sepraspray in a limited number of patients who are under going a laparoscopic myomectomy. Sepraspray will be applied to the organs in the pelvic cavity following laparoscopic myomectomy. We will compare treatment with Sepraspray as a adhesion prevention barrier after laparoscopic myomectomy versus no adhesion barrier.
Conditions Studied
Interventions
- DEVICE Sepraspray
Study Locations (3)
Illinois
- - Naperville
Pennsylvania
- - Philadelphia
Texas
- - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00624390
The ClinicalTrials.gov registry entry for NCT00624390 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Laparoscopic Myomectomy appearing as the primary indexed condition, and to 1 intervention - of which Sepraspray is the first listed.
NCT00624390 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT00624390 about?
NCT00624390 is a clinical study titled "Sepraspray™ Laparoscopic Myomectomy Study". The purpose of this research study is to obtain preliminary data of the safety and effectiveness of Sepraspray in a limited number of patients who are under going a laparoscopic myomectomy. Sepraspray will be applied to the organs in the pelvic cavity following laparoscopic myomectomy. We will compa...
What is the current status of trial NCT00624390?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2007-11. Estimated completion is 2008-12.
What conditions does trial NCT00624390 study?
This clinical trial studies the following conditions: Laparoscopic Myomectomy.
What interventions are being tested in trial NCT00624390?
The interventions under investigation include: Sepraspray (DEVICE).
Who is sponsoring clinical trial NCT00624390?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00624390 being conducted?
This trial has 3 study locations across Illinois, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.